📰 Technology Incubation Program News
Technology Incubation Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Technology Incubation Program. Real-time updates on events, politics, business and more.
February 28, 2024
UConn leadership, medical faculty present groundbreaking research techniques and innovations to legislative committee
December 20, 2023
-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated...
December 20, 2023
-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing ---- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis ---- Company Announces Extension of Runway to 3Q 2025 As Part of Po...
December 9, 2023
-- FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women ---- Study Designed to Provide a Contemporary Control Dataset to Support a Future Registrational Trial in Pregnant Women --NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a cli...
December 9, 2023
-- FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women -- -- Study Designed to Provide a Contemporary Control Dataset to Support a...
November 28, 2023
-- Preliminary Data Support RLYB212 Once Monthly Subcutaneous Dosing in Phase 2 Study -- -- RLYB212 Toxicology Package Complete, Including Maternal-Fetal Toxicology; Key Activity to Support Phase 2...
November 8, 2023
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...
October 3, 2023
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rally...
September 3, 2023
-- First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at 12, 24, and 72 Hours for the 300 mg dose in Healthy Participants ---- Mean Estimated Elimination Half-Life for RLYB116 was > 300 Hours ---- No Severe or Seriou...
August 31, 2023
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...